PrecisionGo enabling cutting-edge Alzheimer’s research

Alzheimer’s disease is one of the greatest health challenges of our generation, with devastating impacts on individuals, families, and communities. In Australia alone, it’s estimated that around 411,100 people are living with dementia in 2023, and this number is projected to more than double by 2058. To change this trajectory, we need not only deeper understanding of disease mechanisms, but also a way to bring discoveries swiftly to the clinical interface through precision medicine.

At The Westmead Institute for Medical Research, Dr Caitlin Finney, Head of Neurodegeneration and Disease Modelling, is leading pioneering research into the biological drivers of Alzheimer’s. Her work is laying the foundations for next-generation therapies designed to slow, prevent, and ultimately stop disease progression.

Her recent award of a major research fellowship reflects both her exceptional leadership and the promise of her research to reshape the future of brain health. By integrating advanced disease modelling with cutting-edge genomics and bioinformatics, Dr Finney is ensuring that breakthroughs in the lab are translated into real-world treatments.

Looking ahead, Dr Finney’s vision is clear: to accelerate the development of new treatments and, ultimately, find a cure for Alzheimer’s disease. Learn more about Dr Finney’s work - https://wimr.org.au/researchers/doctor-caitlin-finney/.

At PrecisionGO, we are proud to support world-leading researchers like Dr Finney who are dedicated to transforming the future of brain health through innovation, collaboration, and compassion.